Gilead Sciences, Inc. vs TKO Group Holdings Inc — how do they compare? Gilead Sciences, Inc. trades at $135.19 (market cap $168.35B), while TKO Group Holdings Inc trades at $194.36 (market cap $14.24B). The key difference: Gilead Sciences, Inc. is far larger — about 11.8× TKO Group Holdings Inc's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.42%). Which is the better fit depends on your goals.
| GILD | TKO | |
|---|---|---|
Market Cap | $168.35B | $14.24B |
Sector | Health | Technology |
52-Week High | $155.80 | $224.96 |
52-Week Low | $110.56 | $176.49 |
Enterprise Value | $191.42B | $18.60B |
Dividend Yield | 2.42% | 1.6% |
Trailing returns across standard periods
Latest headlines on both assets
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →